Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026

Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid-2026 data from its SEABREEZE study.